Clasp Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Clasp Therapeutics - overview
Established
2020
Location
Rockville, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2020, Clasp Therapeutics operates as a biotechnology company focused on immuno-oncology for cancer patients. In March 2024, Clasp Therapeutics raised USD 150 million in series A funding co-led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings, with participation from Vivo Capital, Cure Ventures, Blackbird Ventures, etc. Clasp Therapeutics is revolutionizing immuno-oncology with next-generation T cell engagers (TCEs), focusing on creating precision medicines to treat cancers that don't respond to current treatments. The company goal is on developing personalized treatments that use the immune system to identify and kill cancers with common driver mutations across cancer types.
Clasp's technique targets modification protein fragments found in cancer cells, a concept that has the potential to significantly expand the reach of current immuno-oncology medicines by targeting cancer-driving proteins inside cells that were previously invisible to similar drugs. The company plans to use the March 2024 funding to support the expansion and development of its product.
Current Investors
Alexandria Venture Investments, Novo Holdings, Vivo Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.clasptx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.